Abstract Immune therapy of solid tumors has resulted in remarkable benefits for various tumor entities. It is unclear whether aggressive meningiomas might benefit from immune therapy strategies. Here we report a case of a 79-year old man who received Nivolumab for treatment of metastatic renal cell cancer. During course of Nivolumab treatment, he rapidly developed an atypical meningioma, suggesting that the meningioma growth might be at least not suppressed by Nivolumab. Moreover, this case suggests that aggressive meningiomas can be induced during immune therapy of solid tumors.

中文翻译：

---

Nivolumab治疗转移性肾细胞癌期间非典型脑膜瘤的快速发展

摘要 实体瘤的免疫治疗已为各种肿瘤实体带来显着益处。目前尚不清楚侵袭性脑膜瘤是否可能从免疫治疗策略中受益。在这里，我们报告了一例 79 岁男性接受 Nivolumab 治疗转移性肾细胞癌的病例。在 Nivolumab 治疗过程中，他迅速发展为非典型脑膜瘤，这表明脑膜瘤的生长可能至少不会被 Nivolumab 抑制。此外，该病例表明，在实体瘤的免疫治疗过程中可以诱发侵袭性脑膜瘤。